VITRAKVI (larotrectinib sulfate)
SOLID TUMOR WITH NEUROTROPHIC RECEPTOR TYROSINE KINASE (NTRK) GENE FUSION
LOXO-BAYER
Indication
Solid tumor with neurotrophic receptor tyrosine kinase (NTRK) gene fusion
Solid tumor with neurotrophic receptor tyrosine kinase (NTRK) gene fusion refers to a tissue-agnostic oncologic condition characterized by malignant solid neoplasms in adult or pediatric populations that harbor an abnormal genomic rearrangement involving the NTRK1, NTRK2, or NTRK3 genes. Read more about Solid tumor with neurotrophic receptor tyrosine kinase (NTRK) gene fusion
5 drugs 4 manufacturers
Drugs that treat it
Common Solid tumor with neurotrophic receptor tyrosine kinase (NTRK) gene fusion therapies.
VITRAKVI (larotrectinib sulfate)
SOLID TUMOR WITH NEUROTROPHIC RECEPTOR TYROSINE KINASE (NTRK) GENE FUSION
LOXO-BAYER
VITRAKVI (larotrectinib sulfate)
ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS·SOLID TUMOR WITH NEUROTROPHIC RECEPTOR TYROSINE KINASE (NTRK) GENE FUSION
Bayer HealthCare
ROZLYTREK (entrectinib)
ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS·ROS1 POSITIVE NON-SMALL CELL LUNG CANCER·+1
GENENTECH
AUGTYRO (repotrectinib)
ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS·ROS1 POSITIVE NON-SMALL CELL LUNG CANCER·+1
BMS PRIMARYCARE
Filter & compare in the drug finder →Opens the drug finder with Solid tumor with neurotrophic receptor tyrosine kinase (NTRK) gene fusion preselected.
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonSolid tumor with neurotrophic receptor tyrosine kinase (NTRK) gene fusion refers to a tissue-agnostic oncologic condition characterized by malignant solid neoplasms in adult or pediatric populations that harbor an abnormal genomic rearrangement involving the NTRK1, NTRK2, or NTRK3 genes.
These somatic chromosomal fusions join the kinase domain of a tropomyosin receptor kinase (TRK) protein with an unrelated upstream partner gene.
The resulting chimeric oncoprotein exhibits constitutive, ligand-independent tyrosine kinase activation, which stimulates downstream intracellular signaling cascades—such as the MAPK, PI3K/AKT, and PLC-gamma pathways—to drive uncontrolled cellular proliferation, survival, and tumorigenesis across diverse anatomical sites and histologic subtypes.
- nih.gov
Solid tumor with neurotrophic receptor tyrosine kinase (NTRK) gene fusion refers to a tissue-agnostic oncologic condition characterized by malignant solid neoplasms in adult or pediatric populations that harbor an abnormal genomic rearrangement involving the NTRK1, NTRK2, or NTRK3 genes
- gene.com
Solid tumor with neurotrophic receptor tyrosine kinase (NTRK) gene fusion refers to a tissue-agnostic oncologic condition characterized by malignant solid neoplasms in adult or pediatric populations that harbor an abnormal genomic rearrangement involving the NTRK1, NTRK2, or NTRK3 genes These somatic chromosomal fusions join the kinase domain of a tropomyosin receptor kinase (TRK) protein with an unrelated upstream partner gene The resulting chimeric oncoprotein exhibits constitutive, ligand-ind...
- ucla.edu
The resulting chimeric oncoprotein exhibits constitutive, ligand-independent tyrosine kinase activation, which stimulates downstream intracellular signaling cascades—such as the MAPK, PI3K/AKT, and PLC-gamma pathways—to drive uncontrolled cellular proliferation, survival, and tumorigenesis across diverse anatomical sites and histologic subtypes
Personalize your experience
Follow Solid tumor with neurotrophic receptor tyrosine kinase (NTRK) gene fusion and get updates as they land.
Create a free account
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.